Welcome to our dedicated page for PRF Technologies news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PRF Technologies stock.
PRF Technologies Ltd. reports developments across clinical-stage specialty pharmaceuticals and AI-driven solar analytics. The company focuses on reformulating established therapeutics for post-operative pain management and, through majority-owned LayerBio, is developing OcuRing™-K, a bio-erodible intraocular ring designed to deliver ketorolac for post-cataract pain and inflammation.
PRF news also covers the company’s DeepSolar business unit, which develops AI-driven digital asset management, forecasting, performance monitoring, and technical due diligence tools for utility-scale solar plants. Recurring updates include ocular drug-delivery regulatory milestones, preclinical and clinical safety data, patent activity, SaaS deployments, commercial collaborations, capital actions, and governance changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, will have CEO Ilan Hadar present at the Sequire Investor Summit from April 24-26, 2023, in San Juan, Puerto Rico. Hadar's presentation is scheduled for April 26th at 1:30 PM ET. The summit will feature over 40 presentations from public companies, with opportunities for attendees to engage in one-on-one meetings and networking events. PainReform is focused on reformulating established therapeutics, with PRF-110 as its lead product targeting post-operative pain relief. This product is currently in Phase III clinical trials and utilizes a proprietary drug-delivery system designed for extended pain relief. For more information about the summit, visit puertorico.srax.com.